NAD+ and Sirtuins: The Sinclair Thesis
David Sinclair's information theory of aging has made NAD+ the most talked-about molecule in longevity science. But how much of it is supported by evidence — and how much is marketing?
The Core Thesis
In his 2019 book Lifespan, Harvard geneticist David Sinclair proposes that aging is not an inevitable consequence of wear and tear, but rather a loss of epigenetic information. According to this theory, cells retain their DNA (the "digital" information) but gradually lose the epigenetic instructions (the "analog" information) that tell genes when to turn on and off.
Central to this thesis are sirtuins — a family of seven proteins (SIRT1-7) that act as epigenetic guardians. Sirtuins maintain chromatin structure, silence transposons, and repair DNA. But they need fuel to function: NAD+ (nicotinamide adenine dinucleotide), a coenzyme present in every cell.
The problem: NAD+ levels decline approximately 50% between ages 40 and 60. As NAD+ drops, sirtuins can't do their job, epigenetic information erodes, and aging accelerates. The proposed solution: restore NAD+ levels with precursor supplements like NMN or NR.
NAD+ Biochemistry: The Basics
NAD+ is involved in hundreds of metabolic reactions. Its key roles:
- Energy metabolism: NAD+ accepts electrons in glycolysis and the TCA cycle, becoming NADH, which feeds the mitochondrial electron transport chain to produce ATP.
- Sirtuin activation: Sirtuins are NAD+-dependent deacetylases. They remove acetyl groups from histones and other proteins, affecting gene expression and stress resistance.
- DNA repair: PARP enzymes (especially PARP1) consume NAD+ during DNA repair. With age, increased DNA damage means more NAD+ is consumed for repair, leaving less for sirtuins.
- Immune regulation: CD38, an NAD+-consuming enzyme, increases with age and is a major driver of NAD+ decline. Chronic inflammation drives CD38 expression.
NMN vs NR: The Precursor Debate
There are two main NAD+ precursor supplements:
NMN (Nicotinamide Mononucleotide)
One step closer to NAD+ in the biosynthetic pathway. Sinclair's preferred precursor. Converted to NAD+ by the enzyme NMNAT. Multiple human trials published. Was briefly threatened by FDA classification as a drug (2022) but remains available as a supplement.
Typical dose: 250–1000mg/day
NR (Nicotinamide Riboside)
Two steps from NAD+. Championed by ChromaDex (Tru Niagen) and researched by Charles Brenner. Must first be converted to NMN, then to NAD+. Has its own body of human trial data. May have slightly different tissue distribution than NMN.
Typical dose: 300–1000mg/day
The honest answer: There is no definitive evidence that NMN is superior to NR or vice versa in humans. Both reliably raise blood NAD+ levels. The Sinclair vs. Brenner debate is partly scientific, partly commercial rivalry. Choose based on quality, price, and third-party testing rather than claimed superiority.
What the Human Evidence Actually Shows
What IS well-supported:
- NAD+ levels do decline with age (well-documented)
- NMN and NR supplementation reliably increases blood NAD+ levels (multiple RCTs)
- Sirtuins are real enzymes with real NAD+ dependence (basic biochemistry)
- NAD+ is genuinely important for DNA repair and mitochondrial function
What is UNCERTAIN:
- Whether raising NAD+ in already-healthy humans produces meaningful clinical benefits
- Whether the dramatic mouse results (rejuvenation, endurance) translate to humans
- The optimal dose, timing, and duration of supplementation
- Whether oral NMN/NR reaches tissues in sufficient concentrations
- Long-term safety beyond 1 year
What is NOT supported:
- "Reverse your age by 20 years" — no human trial has shown this
- That NAD+ supplementation is the primary driver of Sinclair's personal results (he also exercises, fasts, etc.)
- That resveratrol meaningfully activates sirtuins in humans (poor bioavailability, Sirtris failed)
The Sinclair Conflict of Interest
We include this section because transparency is foundational to our approach. David Sinclair is:
- Co-founder of Tally Health (sells NMN supplements and biological age tests)
- Co-founder of Metro Biotech (developing NMN-based therapeutics)
- Advisor to InsideTracker (blood biomarker testing)
- Previously co-founded Sirtris Pharmaceuticals (resveratrol-based drugs, sold to GSK for $720M, program later discontinued)
This doesn't mean his science is wrong — his lab produces legitimate, peer-reviewed research. But when a researcher directly profits from the products he advocates, you should weight his public statements differently than his published papers. We do.
Our Assessment
The NAD+/sirtuin axis is real biology, not pseudoscience. NAD+ decline with age is well-documented, and NMN/NR supplementation reliably raises NAD+ levels. However, the leap from "raises a biomarker" to "slows aging in humans" is not yet firmly established. We rate NMN as Moderate Evidence — promising enough to include, honest enough to flag the gaps. The best approach: try it if you're interested, track your biological age before and after, and don't neglect the basics (exercise, sleep, diet) that have far stronger evidence.
Key Sources
- Sinclair DA, LaPlante MD. Lifespan: Why We Age — and Why We Don't Have To. Atria Books, 2019.
- Yoshino J, et al. "NAD+ intermediates: the biology and therapeutic potential." Cell Metabolism, 2018. PubMed
- Igarashi M, et al. "Chronic NMN supplementation elevates blood NAD+ levels." Nature Aging, 2022. PubMed
- Martens CR, et al. "Chronic NR supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications, 2018. PubMed